Executive Summary & Key Takeaways
- Dual Facility Launch: SK pharmteco has completed a major expansion at its Swords, Ireland campus, inaugurating two new facilities: a multi-purpose API plant and a high-potency API (HPAPI) suite.
- Enhanced Capacity: The small-molecule API expansion introduces 26.5 cubic meters of new reactor capacity, featuring 8,000-liter glass-lined batch reactors and a Hastelloy agitated filter dryer.
- High-Potency Focus: The new kilo-scale HPAPI and antibody-drug conjugate (ADC) payload suite operates under strict containment, handling materials with occupational exposure limits (OEL) down to 10 ng/m³.
- Executive and Diplomatic Presence: The ribbon-cutting ceremony in August 2026 was led by CEO Joerg Ahlgrimm, alongside Fingal Mayor Councillor Tony Murphy and South Korean Deputy Head of Mission Sung-min Ko.
- Historical Continuity: Since acquiring the facility from Bristol Myers Squibb in 2017, SK has continually expanded the Irish campus, reinforcing Dublin\'s position in its global CDMO network.
Swords, Ireland: 18 August 2026 - Global contract development and manufacturing organization (CDMO) SK pharmteco has officially opened two new state-of-the-art manufacturing facilities at its Swords campus in County Dublin, Ireland. The completion of these facility expansions marks a major milestone in the company\'s European growth strategy, providing increased capacity and advanced technological capabilities to meet the growing global demand for small-molecule active pharmaceutical ingredients (APIs) and high-potency materials.
The expansions include a new multi-purpose Good Manufacturing Practice (GMP) small-molecule API manufacturing facility and a specialized kilo-scale GMP High-Potency API (HPAPI) and ADC payload facility. Company executives, local government officials, and diplomatic representatives gathered at the Swords campus for an official ribbon-cutting ceremony to celebrate the completion of the project, which transitions from construction and validation into active commercial and clinical supply operations.
Commercial Scale Small-Molecule API Facility
The first of the two new facilities is a multi-purpose GMP small-molecule API plant designed to scale up production for commercial programs. As global pharmaceutical companies work to secure their supply chains and ramp up production of critical therapies, having flexible, large-scale manufacturing capacity is essential. The new facility adds approximately 26.5 cubic meters of reactor capacity to the Swords campus, bringing a substantial boost to the site\'s overall chemical synthesis footprint.
Key equipment installations in the new small-molecule API plant include three 8,000-liter glass-lined batch reactors, which provide the chemical and thermal resistance required for a wide range of synthetic reactions. These reactors are supported by extensive holding, blending, and transfer vessels that ensure seamless process flows. For final product isolation, SK pharmteco has installed a 4.15 square meter Hastelloy agitated filter dryer. Hastelloy, a nickel-chromium-molybdenum alloy, offers exceptional corrosion resistance, making it ideal for handling acidic or highly reactive process solvents. The filter dryer integrates washing, drying, and discharging steps into a single enclosed unit, protecting product integrity and minimizing operator exposure.
By integrating directly with the campus\'s existing utility networks, solvent recovery systems, and waste treatment plants, the new facility maximizes operational efficiency. The design also allows for future expansion, providing space to add further reactor capacity or containment systems as client programs progress from clinical development to commercial manufacturing.
Advanced Kilo-Scale HPAPI and ADC Payload Facility
The second facility represents a major technological leap for the Swords campus, focusing on the high-growth area of high-potency active ingredients. The new kilo-scale GMP HPAPI and ADC payload facility is designed to manufacture ultra-high-potency compounds, which are increasingly used in targeted oncology therapies, immunological treatments, and advanced biological conjugates. Because these compounds are highly active in the human body even in microscopic quantities, manufacturing them requires specialized engineering controls to protect both the operators and the environment.
The HPAPI facility is designed to handle materials with an Occupational Exposure Limit (OEL) as low as 10 nanograms per cubic meter (10 ng/m³). Achieving this level of containment requires a rigorous barrier isolation strategy. The site features advanced rigid and flexible isolators that maintain negative pressure relative to the surrounding cleanrooms, ensuring that potent dust or vapors cannot escape. Operators interact with the process equipment through glove ports, and materials are transferred in and out of the containment suites using split-butterfly valves and rapid transfer ports.
The facility supports batch sizes ranging from 0.5 kilograms to 1.5 kilograms, making it ideal for clinical trials, orphan drug manufacturing, and the production of low-volume, high-value commercial ingredients such as ADC payloads. The manufacturing suite is equipped with glass reactors with capacities up to 30 liters, high-pressure liquid chromatography (HPLC) systems for high-resolution purification, tray drying ovens, and specialized lyophilization (freeze-drying) equipment for stabilizing moisture-sensitive compounds. Located adjacent to the campus\'s existing high-potency development laboratories, the new suite provides a seamless path for molecules transitioning from early-stage clinical development into full GMP commercial production.
The new SK pharmteco corporate name board at the entrance of the expanded Swords biopharmaceutical manufacturing facility in Ireland.
Ribbon-Cutting Ceremony and Strategic Leadership
The official opening of the new facilities was celebrated with a ribbon-cutting ceremony at the Swords campus on 18 August 2026. The event brought together SK pharmteco\'s senior leadership, local government representatives, and international diplomats, highlighting the economic and collaborative importance of the expansion.
Presiding over the ceremony, Joerg Ahlgrimm, Chief Executive Officer of SK pharmteco, remarked on the team\'s achievement:
"Today marks an inspiring milestone for SK pharmteco and a testament to the remarkable dedication of our team here in Swords. This occasion is about recognizing the vision, excellence, and hard work that brought these facilities from blueprint to reality. By expanding our capabilities in both standard small molecules and ultra-high-potency APIs, we are strengthening our ability to support our partners as they develop and launch life-changing therapies." - Joerg Ahlgrimm, Chief Executive Officer, SK pharmteco
The ceremony was also attended by the Mayor of Fingal, Councillor Tony Murphy, who welcomed the investment and the continued job security it brings to the local area. Representing the diplomatic community, Counselor Sung-min Ko, Deputy Head of Mission at the Embassy of the Republic of Korea in Ireland, attended the event, highlighting the strong economic and industrial ties between South Korea and Ireland in the life sciences sector.
Historical Roots and Continued Irish Investment
The expansion at Swords represents the latest chapter in SK\'s decade-long investment in Ireland. The Swords manufacturing campus has a long history in the Irish pharmaceutical landscape, having originally been built and operated by Bristol Myers Squibb (BMS) as a major API manufacturing site. In June 2017, SK biotek (a subsidiary of South Korea\'s SK Inc.) announced a definitive agreement to acquire the Swords plant from BMS, a transaction that was completed by the end of 2017. Employees at the site officially transitioned to SK biotek employment on 1 January 2018.
This acquisition was a landmark event, representing the first time a South Korean pharmaceutical company had invested in a manufacturing facility in Ireland. The Irish government, through IDA Ireland, strongly supported the acquisition, recognizing it as a key step in diversifying the country\'s foreign direct investment portfolio and establishing new bridges to Asian biopharma leaders.
Over the years, the site\'s operations were integrated into SK pharmteco, a global CDMO established by SK Inc. to unite its manufacturing assets across the United States, Europe, and Asia. Today, SK pharmteco operates facilities in South Korea, the United States, France, and Ireland, providing global reach and dual-sourcing options for pharmaceutical clients. The Swords campus has continually benefited from this global structure, receiving regular capital investments to upgrade its automation systems, expand its chemical synthesis capacity, and introduce high-potency capabilities.
Comparing the New Facilities: Technical Specifications
To provide a clear overview of the expansion, the table below compares the technical specifications, equipment, and targeted applications of the two new facilities at the Swords campus:
| Technical Parameter | GMP Small-Molecule API Facility | Kilo-Scale GMP HPAPI & ADC Payload Facility |
|---|---|---|
| Primary Purpose | Commercial scale chemical synthesis and API manufacturing | Clinical and low-volume commercial HPAPI and ADC payload manufacturing |
| Reactor Capacity | 26.5 cubic meters (reactor volume) | Glass reactors up to 30 liters |
| Reactor Types | Three 8,000-liter glass-lined batch reactors | High-grade glass and specialized alloy process vessels |
| Product Isolation | 4.15 square meter Hastelloy agitated filter dryer | High-pressure liquid chromatography, tray drying, lyophilization |
| Containment Level (OEL) | Standard chemical exposure limits | Ultra-low exposure limits down to 10 ng/m³ |
| Typical Batch Size | Commercial scale (hundreds of kilograms) | Kilo-scale (0.5 kilograms to 1.5 kilograms) |
Frequently Asked Questions (FAQ)
Q1: What are the main facilities added in the SK pharmteco Swords expansion?
The expansion adds two primary facilities: a multipurpose GMP small-molecule API manufacturing facility adding 26.5 cubic meters of reactor capacity, and a kilo-scale GMP HPAPI and ADC payload facility designed for ultra-high-potency ingredients.
Q2: What is the containment level of the new HPAPI facility?
The kilo-scale HPAPI facility is designed to handle highly potent active ingredients with occupational exposure limits (OELs) as low as 10 nanograms per cubic meter (10 ng/m³), utilizing rigid and flexible barrier isolators to ensure safety.
Q3: How does the new small-molecule plant improve product filtration and drying?
The facility is equipped with a 4.15 square meter agitated filter dryer made of Hastelloy, a highly corrosion-resistant nickel-chromium-molybdenum alloy. This unit integrates washing, filtration, and drying steps in a fully enclosed environment to optimize process flow and safety.
Q4: What is the history of SK pharmteco\'s Swords manufacturing campus?
The Swords campus was originally built and operated by Bristol Myers Squibb. In June 2017, SK biotek announced its acquisition of the site, marking the first time a South Korean company invested in a pharmaceutical manufacturing facility in Ireland. The facility subsequently became part of SK pharmteco\'s global CDMO network.
